Related Experiment Video

Updated: Oct 18, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.7K

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

Marwan Kwok1,2, Angelo Agathanggelou1, Nicholas Davies1

  • 1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.

Cancers
|September 28, 2021
PubMed

Insights

The p53 pathway is crucial for genome integrity and a key target in chronic lymphocytic leukemia (CLL). Research explores strategies to target p53 defects for effective cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 pathway is vital for maintaining genome integrity.
  • Functional loss of p53 is common in chronic lymphocytic leukemia (CLL), driving disease progression and treatment resistance.
  • Targeting the p53 pathway is a significant challenge in cancer research.

Purpose of the Study:

  • To review the biological and clinical significance of p53 pathway defects in CLL.
  • To examine current and emerging therapeutic strategies targeting the p53 pathway in CLL.
  • To evaluate the potential and limitations of these novel therapies.

Main Methods:

  • Literature review of studies on p53 pathway in CLL.
  • Analysis of therapeutic strategies including p53 upregulation, restoration, synthetic lethality, and immunotherapy.
  • Appraisal of clinical implications and future directions.

Main Results:

  • Defects in the p53 pathway are strongly linked to CLL evolution and resistance to therapy.
  • Multiple strategies are being developed to target p53, including restoring its function and exploiting pathway vulnerabilities.
  • Harnessing p53 immunogenicity presents a novel therapeutic avenue.

Conclusions:

  • Targeting the p53 pathway holds great promise for treating CLL, despite challenges.
  • Evaluating the efficacy and safety of p53-targeted therapies is crucial for their integration into CLL treatment regimens.
  • Further research is needed to optimize these strategies and overcome therapeutic resistance.
Keywords:
ATMATRCDKDNA-PKMDM2PARPUSP7immunityp53synthetic lethality

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.7K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.5K